PCSK9 inhibitors
Advertisement
Adverse cardiovascular outcomes were more prevalent among patients with rejected or abandoned PCSK9 inhibitor ...
A recent analysis of the results of the ODYSSEY OUTCOMES trail suggests that the PCSK9 inhibitor alirocumab added to ...
This week's edition features articles with expert commentary by Chris Cannon, MD, a cardiologist at Brigham and Women's ...
A new brief report in JAMA Cardiology suggests that the PCSK9 inhibitor evolocumab paired with adequate background ...
Results from a recent cohort study suggest that evolocumab was associated with a 50% reduction in low-density ...
DocWire News talks with Chris Cannon, MD, cardiologist and professor of medicine at Harvard Medical School and a ...
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.